Monoclonal antibodies targeting immune checkpoints CTLA‐4, PD‐1 and PD‐L1, referred to as immune checkpoint inhibitors (ICIs), have become a new standard of care in a wide range of cancers [1, 2, 3, 4]. The gene discussed is PDCD1; the disease is cancer.